YX0798是一种高强度,选择性和口服有效的CDK9抑制剂,用于治疗侵袭性淋巴瘤
Vivian Jiang1, Yu Xue2, Hong Kim1
1The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Blood advances
|July 21, 2025
概括
一种新型药物YX0798,向循环素依赖性激酶9 (CDK9),通过重编程转录和克服治疗耐药性来对抗地幔细胞淋巴瘤 (MCL),显示出口服的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非遗传转录变化驱动瘤进展和治疗耐药性.
- 循环素依赖性激酶9 (CDK9) 调节RNA聚合酶II的转录,其功能障碍导致转录基因的改变.
- HSP90-MYC-CDK9网络有助于在上衣细胞淋巴瘤 (MCL) 中的治疗耐药性.
研究的目的:
- 调查YX0798的治疗潜力,一种新的CDK9抑制剂,用于地幔细胞淋巴瘤 (MCL).
- 在临床前模型中评估YX0798的选择性,口服生物可用性和抗瘤功效.
- 阐明YX0798抗癌活性背后的分子机制.
主要方法:
- 发现和结构优化YX0798作为选择性CDK9抑制剂.
- 在体外评估目标选择性和结合亲和力.
- 在体内研究评估口服,抗瘤活性和MCL模型中的治疗耐药性.
- 机制研究包括基因表达分析和细胞循环中断评估.
主要成果:
- YX0798表现出显著的选择性和对CDK9.9的高度亲和力.
- 口服YX0798显示出显著的抗瘤活性,并克服了体内治疗阻力.
- YX0798降低了c-MYC和MCL-1的调节,破坏了细胞循环,并诱导转录基因重编程导致细胞死亡.
- YX0798显示了组合疗法的潜力,以提高治疗疗效.
结论:
- YX0798是一种强效,口服生物可用和选择性CDK9抑制剂,在MCL中具有显著的抗瘤活性.
- YX0798通过重编程转录,降低关键上蛋白的调节和诱导癌细胞死亡来发挥作用.
- YX0798代表了MCL的有希望的治疗候选者,有可能改善治疗结果并克服耐药性.
相关概念视频
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K